CN113365699A - 靶向泛素化降解brd4蛋白化合物及其制备方法和应用 - Google Patents

靶向泛素化降解brd4蛋白化合物及其制备方法和应用 Download PDF

Info

Publication number
CN113365699A
CN113365699A CN202080012258.7A CN202080012258A CN113365699A CN 113365699 A CN113365699 A CN 113365699A CN 202080012258 A CN202080012258 A CN 202080012258A CN 113365699 A CN113365699 A CN 113365699A
Authority
CN
China
Prior art keywords
membered
substituted
compound
amino
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080012258.7A
Other languages
English (en)
Inventor
赵传武
蒋春华
张颜
张雪娇
杨金路
康杰琼
赵培培
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Original Assignee
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd filed Critical CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Publication of CN113365699A publication Critical patent/CN113365699A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

本发明涉及一种式(I)所示的化合物或其互变异构体、光学异构体、氘代物、氮氧化物、溶剂化物、药学上可接受的盐或前药，所述化合物的制备方法，包含其的药物组合物及所述化合物或药物组合物在制备在制备用于预防和/或治疗癌症、肿瘤、病毒感染、抑郁症、神经性病症、创伤、年龄相关的白内障、器官移植排斥或自身免疫疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202080012258.7A 2019-02-02 2020-02-03 靶向泛素化降解brd4蛋白化合物及其制备方法和应用 Pending CN113365699A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019101068748 2019-02-02
CN201910106874 2019-02-02
PCT/CN2020/000027 WO2020156017A1 (zh) 2019-02-02 2020-02-03 靶向泛素化降解brd4蛋白化合物及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN113365699A true CN113365699A (zh) 2021-09-07

Family

ID=71840802

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080012258.7A Pending CN113365699A (zh) 2019-02-02 2020-02-03 靶向泛素化降解brd4蛋白化合物及其制备方法和应用

Country Status (5)

Country Link
US (1) US20220135589A1 (zh)
EP (1) EP3919127A4 (zh)
JP (1) JP7394140B2 (zh)
CN (1) CN113365699A (zh)
WO (1) WO2020156017A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107257800A (zh) * 2014-12-23 2017-10-17 达纳-法伯癌症研究所股份有限公司 通过双功能分子诱导靶蛋白降解的方法
CN108136044A (zh) * 2015-06-04 2018-06-08 阿尔维纳斯股份有限公司 基于酰亚胺的蛋白水解调节剂和相关使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120009141A1 (en) * 2008-08-07 2012-01-12 Pharmascience Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
TWI530499B (zh) * 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
KR20240038809A (ko) * 2014-04-14 2024-03-25 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
CN108350062B (zh) * 2015-08-06 2022-10-14 达纳-法伯癌症研究所股份有限公司 靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9809603B1 (en) * 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
CN106905347B (zh) 2017-04-18 2019-04-16 四川大学 Brd4抑制剂及其在肿瘤治疗药物中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107257800A (zh) * 2014-12-23 2017-10-17 达纳-法伯癌症研究所股份有限公司 通过双功能分子诱导靶蛋白降解的方法
CN108136044A (zh) * 2015-06-04 2018-06-08 阿尔维纳斯股份有限公司 基于酰亚胺的蛋白水解调节剂和相关使用方法

Also Published As

Publication number Publication date
JP7394140B2 (ja) 2023-12-07
WO2020156017A1 (zh) 2020-08-06
US20220135589A1 (en) 2022-05-05
EP3919127A4 (en) 2022-12-07
EP3919127A1 (en) 2021-12-08
JP2022523738A (ja) 2022-04-26

Similar Documents

Publication Publication Date Title
CN111484477B (zh) 一种苯并吡啶酮杂环化合物及其用途
RU2622104C2 (ru) Макроциклические ингибиторы киназы lrrk2
WO2017092635A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
JPWO2004096806A1 (ja) 縮合イミダゾール誘導体
RU2720488C2 (ru) Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия
EP4269405A1 (en) Preparation and application method of heterocyclic compound as kras inhibitor
KR20100085107A (ko) 리버스턴 유사체의 신규 화합물 및 그의 용도(3)
CN110194770B (zh) 肽酰精氨酸脱亚胺酶抑制剂及其用途
CN112430234A (zh) 一种新型kras g12c蛋白抑制剂及其制备方法和用途
CN112300153B (zh) 一种杂环化合物、药物组合物和用途
CN110945000A (zh) 含有氨基吡唑并嘧啶的大环化合物及其药物组合物和用途
JP2021519828A (ja) ジアリール大員環化合物、医薬組成物及びその用途
WO2023280136A1 (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
EP1659123A1 (en) Bicyclic pyrazole derivative
CN108299420B (zh) 作为选择性雌激素受体下调剂的五环类化合物及其应用
CN114685488A (zh) 作为sos1抑制剂的化合物及其应用
CN114437116A (zh) 杂环化合物及其制备方法、药物组合物和应用
KR20210103973A (ko) 단백질 키나아제 분해 유도 화합물 및 이의 용도
CN109111439B (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
CN113365699A (zh) 靶向泛素化降解brd4蛋白化合物及其制备方法和应用
CN113527311B (zh) Fgfr4抑制剂、组合物及其在药物制备中的用途
CN114409636B (zh) 一种喹唑啉酮化合物或其药学上可接受的盐及其制备方法和应用
JP2018518536A (ja) 選択的抗癌化合物
CN113979999B (zh) 靶向泛素化降解bcr-abl激酶的化合物及其制备方法、组合物和用途
CN115427407A (zh) 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40051966

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination